Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the 11 Best Short-Term Stocks to Invest in. A definitive merger agreement announced in the first week of August drives a short-term surge in the ...
Dow Jones futures rose slightly early Wednesday, along with S&P 500 futures and Nasdaq futures. NOW PLAYING Stocks Fall On AI Worries, Pare Losses. Oracle, SoFi, Alnylam Pharmaceuticals In Focus.
Brookline initiated coverage of Y-mAbs Therapeutics (YMAB) with a Buy rating and $17 price target Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results